Summary:
Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (RECOVER)
Qualified Participants Must:
• Have a newly diagnosed, histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer
•
Be a candidate to receive adjuvant or neoadjuvant TC chemotherapy.
•
Be at least 18 years of age.
•
Be Male or Female
Qualified Participants May Receive:
Participants who enroll in the trial with receive study treatment a no cost to them and may recieve compensation for their time and travel